Patients with invasive lobular and ductal carcinoma or pleomorphic lobular carcinoma might increase pathologic complete response rate and lower mastectomy rates compared to classical lobular type

摘要

I wish to congratulate Tamirisa et al for their article in which they investigated the impact of chemotherapy sequence on survival by comparing node-positive invasive lobular carcinoma (ILC) patients who received neoadjuvant (NACT) and adjuvant (ACT) chemotherapy. They reported that NACT yielded low rates of pCR, was not associated with lower rates of mastectomy or less extensive axillary surgery, and was associated with worse survival vs ACT. The authors did not mention the rates of ILC + invasive ductal carcinoma or pleomorphic lobular carcinoma in both ACT or NACT groups. These specific groups might increase pCR and lower mastectomy rates compared to classical ILC. This issue merits further investigation.